中华实验和临床病毒学杂志
中華實驗和臨床病毒學雜誌
중화실험화림상병독학잡지
CHINESE JOURNAL OF EXPERIMENTAL AND CLINICAL VIROLOGY
2014年
6期
443-445
,共3页
糖皮质激素类%主动转运,细胞核%肿瘤坏死因子
糖皮質激素類%主動轉運,細胞覈%腫瘤壞死因子
당피질격소류%주동전운,세포핵%종류배사인자
Glucocorticoids%Active transport,cell nucleus%Tumor necrosis factor
目的 探讨阿昔洛韦联合地塞米松治疗小鼠单纯疱疹病毒性脑炎的疗效及作用机制.方法 BALB/c小鼠随机分为正常对照组、模型对照组、阿昔洛韦单药治疗组及阿昔洛韦联合地塞米松治疗组,阿昔洛韦组和联合治疗组小鼠给予阿昔洛韦灌胃,正常对照组和模型对照组给予生理盐水灌胃;建模后第3天,联合治疗组给予地塞米松腹腔注射,其他各组给予生理盐水腹腔注射,连续给药至建模后第7天.对各组小鼠进行神经症状评分并测定小鼠脑组织中核转录因子-κB及肿瘤坏死因子-α的蛋白表达,连续12 d观察各组小鼠进行生存分析研究.结果 建模7天后,模型组小鼠神经症状评分最高,联合治疗组神经症状评分最低,阿昔洛韦组介于两者之间,组间差异有统计学意义(P<0.05);模型组小鼠全部死亡,联合治疗组生存率明显高于阿昔洛韦组;模型对照组小鼠脑组织中核转录因子-κB及肿瘤坏死因子-α表达量明显高于正常对照组,阿昔洛韦组及联合治疗组均明显下降,且组间差异有统计学意义(P<0.05).结论 阿昔洛韦联合地塞米松治疗小鼠单纯疱疹病毒性脑炎,较阿昔洛韦单药治疗效果明显,表现为小鼠生存率显著提高,神经症状减轻,及在蛋白水平上明显抑制单纯疱疹病毒性脑炎小鼠脑组织中核转录因子-κB及肿瘤坏死因子-α的过表达.
目的 探討阿昔洛韋聯閤地塞米鬆治療小鼠單純皰疹病毒性腦炎的療效及作用機製.方法 BALB/c小鼠隨機分為正常對照組、模型對照組、阿昔洛韋單藥治療組及阿昔洛韋聯閤地塞米鬆治療組,阿昔洛韋組和聯閤治療組小鼠給予阿昔洛韋灌胃,正常對照組和模型對照組給予生理鹽水灌胃;建模後第3天,聯閤治療組給予地塞米鬆腹腔註射,其他各組給予生理鹽水腹腔註射,連續給藥至建模後第7天.對各組小鼠進行神經癥狀評分併測定小鼠腦組織中覈轉錄因子-κB及腫瘤壞死因子-α的蛋白錶達,連續12 d觀察各組小鼠進行生存分析研究.結果 建模7天後,模型組小鼠神經癥狀評分最高,聯閤治療組神經癥狀評分最低,阿昔洛韋組介于兩者之間,組間差異有統計學意義(P<0.05);模型組小鼠全部死亡,聯閤治療組生存率明顯高于阿昔洛韋組;模型對照組小鼠腦組織中覈轉錄因子-κB及腫瘤壞死因子-α錶達量明顯高于正常對照組,阿昔洛韋組及聯閤治療組均明顯下降,且組間差異有統計學意義(P<0.05).結論 阿昔洛韋聯閤地塞米鬆治療小鼠單純皰疹病毒性腦炎,較阿昔洛韋單藥治療效果明顯,錶現為小鼠生存率顯著提高,神經癥狀減輕,及在蛋白水平上明顯抑製單純皰疹病毒性腦炎小鼠腦組織中覈轉錄因子-κB及腫瘤壞死因子-α的過錶達.
목적 탐토아석락위연합지새미송치료소서단순포진병독성뇌염적료효급작용궤제.방법 BALB/c소서수궤분위정상대조조、모형대조조、아석락위단약치료조급아석락위연합지새미송치료조,아석락위조화연합치료조소서급여아석락위관위,정상대조조화모형대조조급여생리염수관위;건모후제3천,연합치료조급여지새미송복강주사,기타각조급여생리염수복강주사,련속급약지건모후제7천.대각조소서진행신경증상평분병측정소서뇌조직중핵전록인자-κB급종류배사인자-α적단백표체,련속12 d관찰각조소서진행생존분석연구.결과 건모7천후,모형조소서신경증상평분최고,연합치료조신경증상평분최저,아석락위조개우량자지간,조간차이유통계학의의(P<0.05);모형조소서전부사망,연합치료조생존솔명현고우아석락위조;모형대조조소서뇌조직중핵전록인자-κB급종류배사인자-α표체량명현고우정상대조조,아석락위조급연합치료조균명현하강,차조간차이유통계학의의(P<0.05).결론 아석락위연합지새미송치료소서단순포진병독성뇌염,교아석락위단약치료효과명현,표현위소서생존솔현저제고,신경증상감경,급재단백수평상명현억제단순포진병독성뇌염소서뇌조직중핵전록인자-κB급종류배사인자-α적과표체.
Objective To investigate the efficacy and mechanism of acyclovir combined with dexamethasone for the treatment of herpes simplex virus encephalitis in mice.Method BALB/c mice were randomized into normal control group,model group,acyclovir monotherapy group and acyclovir combined with dexamethasone treatment group.Since the first day after modeling,mice in the acyclovir group and combined treatment group administered acyclovir by garage,normal control group and model control group received normal saline,since the third day after modeling,the combined treatment group given dexamethasone by intraperitoneal injection,other groups received saline intraperitoneally.The administration continued until the seventh day after modeling.The neurological symptom score and protein expression of nuclear transcription factor-κB and tumor necrosis factor-α were measured on the third,fifth and seventh day after modeling,the cumulative probability of mice survival were analyzed for 12 days.Results 7 days after modeling,neurological symptoms score of model group was highest of all,that of the combined treatment group was the lowest,the acyclovir group was in the middle,there was significant differences (P < 0.05) between any two groups.12 days after modeling,all the mice in the model group died,survival rate of combined treatment group was significantly higher than that of acyclovir group.7 days after modeling,the protein expression level of nuclear transcription factor-κB and tumor necrosis factor-α of the model group were significantly higher than the normal control group,that of the acyclovir group and combined treatment group were significantly decreased,and there was statistically significant differences (P < 0.05) between groups.Conclusion Acyclovir combined with dexamethasone in the treatment of mice with herpes simplex virus encephalitis could exhibited better effect than acyclovir monotherapy.